Lusutrombopag|S-888711|TPO receptor agonist

Page 1

Website:www.dcchemicals.com Email: info@dcchemicals.com Phone:+86-21-58447131 Marketing Center: Room 610,Building 15, Jinxiang Rd 201, Shanghai, China

Datasheet of Lusutrombopag(S-888711)

Description: Lusutrombopag, also known as S-888711, is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery. Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels. In September 2015, lusutrombopag received its first global approval in Japan for the improvement of CLD-associated thrombocytopenia in patients scheduled to undergo elective invasive procedures.

Chemical Information Catalog

DC9938

Purity of current batch:

>98%

Molecular Weight (MW)

591.54

Molecular Formula

C29H32Cl2N2O5S

CAS No.

1110766-97-6

Solubility (25°C)

DMSO

Storage

Store at -20°C (desiccating conditions).

Handling: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months. Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.